Stay updated on Pembrolizumab Comb. with Docetaxel in Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Comb. with Docetaxel in Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Comb. with Docetaxel in Head & Neck Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:23:00.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a shift in the median survival time of patients with locoregionally unresectable recurrent or metastatic head and neck cancer after platinum failure, potentially due to the combination of docetaxel and pembrolizumab being tested for its effectiveness and safety.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:16.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as age, health condition, and prior treatments. Previously, this section only indicated that no information was provided.
    Difference
    45%
    Check dated 2024-05-22T20:27:45.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:01:32.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Comb. with Docetaxel in Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Comb. with Docetaxel in Head & Neck Cancer Clinical Trial page.